Eli Lilly's weight loss drug slashes the risk of diabetes in long-term trial

Efficacy and “wonder drug” framing

• Many commenters describe GLP‑1 drugs (Ozempic/semaglutide, Mounjaro/Zepbound/tirzepatide) as the closest thing to a 21st‑century “wonder drug” for obesity and diabetes.
• Users report dramatic weight loss and much better blood‑sugar control where diet, exercise, and older drugs failed.
• Some see them as non‑surgical alternatives to bariatric procedures.

Mechanism: appetite, brain, and behavior

• Drugs are GLP‑1 (and in tirzepatide’s case, GLP‑1 + GIP) receptor agonists; they reduce appetite, slow gastric emptying, and blunt blood‑sugar spikes.
• Debate: are they “chemically induced intermittent fasting,” generic calorie restriction, or qualitatively different? Consensus: they enforce a calorie deficit mainly by reducing hunger and cravings.
• Some emphasize that hormones/biochemistry, not just “discipline,” underpin eating behavior.

Side effects and long‑term risks

• Commonly reported: GI issues (nausea), possible muscle and lean‑mass loss, potential bone‑density reduction, and retinal concerns in diabetics with rapidly improved glucose.
• One view: decades of GLP‑1 study suggest low overall risk; others insist “you don’t get something for nothing” and worry about yet‑unknown chronic effects.

Durability, regain, and treatment length

• Stopping often leads to return of appetite and weight regain, similar to other weight‑loss methods.
• Some see lifetime use as likely; others hope for “reset” of habits plus exercise (especially strength training) to maintain results.

Cost, patents, and systemic healthcare effects

• Current U.S. prices (~$10–12k/year) are seen as prohibitive; cheaper in some other countries and via compounding pharmacies.
• Discussion of patent timelines and expectation that generics will transform access.
• Unclear net impact on healthcare costs: fewer obesity/diabetes complications vs more people living long enough to incur other expensive conditions.
• Skepticism that U.S. insurance premiums will fall even if population health improves.

Obesity, responsibility, and food environment

• Strong disagreement over “just eat less and move more” vs acknowledging structural and psychological barriers (hyperpalatable food environment, stress, poverty).
• Several argue drugs are necessary to counteract an obesogenic system; others push for systemic fixes to food supply and policy akin to tobacco control.

Eligibility and anecdotes

• Non‑diabetics with obesity are using these drugs; many report unprecedented control over urges, while some still crave “bad” foods.
• Mixed views on using them for modest weight loss vs reserving for obesity and diabetes.